FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309449754> ?p ?o ?g. }

• W4309449754 abstract "Summary Background The emergence of SARS-CoV-2 variants has significantly reduced the efficacy of some approved vaccines. A fourth dose of NVX-CoV2373 (5µg SARS-CoV-2 rS + 50µg Matrix-M™ adjuvant) was evaluated to determine induction of cross-reactive antibodies to variants of concern. Methods A phase 2 randomized study assessed a fourth dose of NVX-CoV2373 in adults 18–84 years of age (2-dose primary series followed by third and fourth doses at 6-month intervals). Local/systemic reactogenicity was assessed the day of vaccination and for 6 days thereafter. Unsolicited adverse events (AEs) were reported. Immunogenicity was measured before, and 14 days after, fourth dose administration using anti-spike neutralization assays against the ancestral SARS-CoV-2 strain and Omicron sublineages. Antigenic cartography assessed antigenic distances between ancestral and variant strains. Results Among 1283 enrolled participants, 258 were randomized to receive the 2-dose primary series, of whom 104 received a third dose, and 45 received a fourth dose of NVX-CoV2373. The incidence of local/systemic reactogenicity events increased after the first three doses of NVX-CoV2373, and leveled off after dose four. Unsolicited AEs were reported in 9% of participants after dose 4 (none severe or serious). Neutralization antibody titers increased following booster doses. Antigenic cartography demonstrated reductions in antigenic distance between ancestral and variant SARS-CoV-2 strains with increased number of NVX-CoV2373 doses. Conclusions A fourth dose of NVX-CoV2373 enhanced immunogenicity without increasing reactogenicity. Antigenic cartography demonstrated a more universal-like response against SARS-CoV-2 variants after a fourth dose of NVX-CoV2373, indicating that updates to the vaccine composition may not be warranted. Trial registration number NCT04368988" @default.
• W4309449754 created "2022-11-28" @default.
• W4309449754 creator A5000458556 @default.
• W4309449754 creator A5001644964 @default.
• W4309449754 creator A5002761122 @default.
• W4309449754 creator A5011807899 @default.
• W4309449754 creator A5016041349 @default.
• W4309449754 creator A5017931794 @default.
• W4309449754 creator A5023414888 @default.
• W4309449754 creator A5032295889 @default.
• W4309449754 creator A5034631208 @default.
• W4309449754 creator A5047086878 @default.
• W4309449754 creator A5049862354 @default.
• W4309449754 creator A5058673130 @default.
• W4309449754 creator A5074394976 @default.
• W4309449754 creator A5078561694 @default.
• W4309449754 creator A5080207020 @default.
• W4309449754 creator A5081746974 @default.
• W4309449754 date "2022-11-20" @default.
• W4309449754 modified "2023-09-27" @default.
• W4309449754 title "Immunogenicity and safety of a 4^thhomologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized, placebo-controlled trial" @default.
• W4309449754 cites W1979158913 @default.
• W4309449754 cites W2190981469 @default.
• W4309449754 cites W2749306127 @default.
• W4309449754 cites W2808629568 @default.
• W4309449754 cites W3008187404 @default.
• W4309449754 cites W3203630421 @default.
• W4309449754 cites W4200325717 @default.
• W4309449754 cites W4206611537 @default.
• W4309449754 cites W4211200665 @default.
• W4309449754 cites W4214657299 @default.
• W4309449754 cites W4220734224 @default.
• W4309449754 cites W4220988150 @default.
• W4309449754 cites W4223451368 @default.
• W4309449754 cites W4224984590 @default.
• W4309449754 cites W4226023532 @default.
• W4309449754 cites W4229458272 @default.
• W4309449754 cites W4283817451 @default.
• W4309449754 cites W4284886202 @default.
• W4309449754 doi "https://doi.org/10.1101/2022.11.18.22282414" @default.
• W4309449754 hasPublicationYear "2022" @default.
• W4309449754 type Work @default.
• W4309449754 citedByCount "0" @default.
• W4309449754 crossrefType "posted-content" @default.
• W4309449754 hasAuthorship W4309449754A5000458556 @default.
• W4309449754 hasAuthorship W4309449754A5001644964 @default.
• W4309449754 hasAuthorship W4309449754A5002761122 @default.
• W4309449754 hasAuthorship W4309449754A5011807899 @default.
• W4309449754 hasAuthorship W4309449754A5016041349 @default.
• W4309449754 hasAuthorship W4309449754A5017931794 @default.
• W4309449754 hasAuthorship W4309449754A5023414888 @default.
• W4309449754 hasAuthorship W4309449754A5032295889 @default.
• W4309449754 hasAuthorship W4309449754A5034631208 @default.
• W4309449754 hasAuthorship W4309449754A5047086878 @default.
• W4309449754 hasAuthorship W4309449754A5049862354 @default.
• W4309449754 hasAuthorship W4309449754A5058673130 @default.
• W4309449754 hasAuthorship W4309449754A5074394976 @default.
• W4309449754 hasAuthorship W4309449754A5078561694 @default.
• W4309449754 hasAuthorship W4309449754A5080207020 @default.
• W4309449754 hasAuthorship W4309449754A5081746974 @default.
• W4309449754 hasBestOaLocation W43094497541 @default.
• W4309449754 hasConcept C12590561 @default.
• W4309449754 hasConcept C126322002 @default.
• W4309449754 hasConcept C142724271 @default.
• W4309449754 hasConcept C147483822 @default.
• W4309449754 hasConcept C149857219 @default.
• W4309449754 hasConcept C159047783 @default.
• W4309449754 hasConcept C159654299 @default.
• W4309449754 hasConcept C167508917 @default.
• W4309449754 hasConcept C168563851 @default.
• W4309449754 hasConcept C197934379 @default.
• W4309449754 hasConcept C203014093 @default.
• W4309449754 hasConcept C204787440 @default.
• W4309449754 hasConcept C22070199 @default.
• W4309449754 hasConcept C27081682 @default.
• W4309449754 hasConcept C2777289321 @default.
• W4309449754 hasConcept C2777704310 @default.
• W4309449754 hasConcept C2777863537 @default.
• W4309449754 hasConcept C2778375690 @default.
• W4309449754 hasConcept C2780801004 @default.
• W4309449754 hasConcept C2780868878 @default.
• W4309449754 hasConcept C2989005 @default.
• W4309449754 hasConcept C32611913 @default.
• W4309449754 hasConcept C71924100 @default.
• W4309449754 hasConceptScore W4309449754C12590561 @default.
• W4309449754 hasConceptScore W4309449754C126322002 @default.
• W4309449754 hasConceptScore W4309449754C142724271 @default.
• W4309449754 hasConceptScore W4309449754C147483822 @default.
• W4309449754 hasConceptScore W4309449754C149857219 @default.
• W4309449754 hasConceptScore W4309449754C159047783 @default.
• W4309449754 hasConceptScore W4309449754C159654299 @default.
• W4309449754 hasConceptScore W4309449754C167508917 @default.
• W4309449754 hasConceptScore W4309449754C168563851 @default.
• W4309449754 hasConceptScore W4309449754C197934379 @default.
• W4309449754 hasConceptScore W4309449754C203014093 @default.
• W4309449754 hasConceptScore W4309449754C204787440 @default.
• W4309449754 hasConceptScore W4309449754C22070199 @default.
• W4309449754 hasConceptScore W4309449754C27081682 @default.
• W4309449754 hasConceptScore W4309449754C2777289321 @default.
• W4309449754 hasConceptScore W4309449754C2777704310 @default.

• next